Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

Journal of Infectious Diseases

Volumn 190, Issue 5, 2004, Pages 903-907

  Lee, Deborah ^a   Graham, Barney S ^c   Chiu, Ya Lin ^a   Gilbert, Peter B ^a   McElrath, M Juliana ^a,b   Belshe, Robert B ^d   Buchbinder, Susan P ^e   Sheppard, Haynes W ^f   Koblin, Beryl A ^g   Mayer, Kenneth H ^i,j   Keefer, Michael C ^h   Mulligan, Mark J ^k   Celum, Connie L ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e S Francisco Dept of Public Health   (United States)

^f VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^g NEW YORK BLOOD CENTER   (United States)

^h UNIVERSITY OF ROCHESTER   (United States)

ⁱ BROWN UNIVERSITY   (United States)

^j FENWAY INSTITUTE   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CANARYPOX HIV 1 VACCINE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VECTOR;

ARTICLE; CANARYPOX VIRUS; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VACCINATION;

AIDS VACCINES; AVIPOXVIRUS; DOUBLE-BLIND METHOD; FEMALE; GENETIC VECTORS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MALE; RECOMBINANT PROTEINS; RNA, VIRAL;

EID: 4344693298     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/423284     Document Type: Article

References (17)

1. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183:1343-52.
2. Barouch DH, Santra S, Kuroda MJ, et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001; 75:5151-8.
3. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-9.
4. Barouch DH, Kunstman J, Glowczwskie J, et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-75.
5. Graham BS, McElrath MJ, Connor RI, et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group and the Correlates of HIV Immune Protection Group. J Infect Dis 1998; 177:310-9.
6. Connor RI, Korber BT, Graham BS, et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998; 72:1552-76.
7. Berman PW, Gray AM, Wrin T, et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis 1997; 176:384-97.
8. de Bruyn G, Rossini AJ, Chiu Y-L, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22:704-13.
9. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-46.
10. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002; 29:254-61.
11. + responses following immunization by measuring the effector population IFNγ production. Immunol Lett 2001; 77:7-15.
12. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003; 188:179-93.
13. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-80.
14. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 2001; 183:23-35.
15. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-20.
16. Seage GR 3rd, Holte SE, Metzger DS, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001; 153:619-27.
17. Fitzgerald DW, Pape JW, Wasserheit JN, Counts GW, Corey L. Provision of treatment in HIV-1 vaccine trials in developing countries. Lancet 2003; 362:993-4.